Itonis Inc (ITNS)

[surehands]

The annual report has indication of chronic disease solution or intent (MJ):


E. principal products or services, and their markets;
In August 2012, the Company launched a new Itonis Pharmaceuticals
division headed by Dr. Charles Hensley, Ph.D. to produce and market
over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has placed a
manufacturing order for the first batch of its Emesyl™ product line. The Company has identified the market for its Emesyl™ product line as the general public who suffers from nausea.